Infinity Pharmaceuticals, Inc. and MedImmune, Inc. Announce Issuance of U.S. Patent for Proprietary Heat Shock Protein 90 Inhibitors

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 23, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. today announced that the United States Patent and Trademark Office issued a patent on October 16, 2007 for the companies' heat shock protein 90 (Hsp90) inhibitors, including investigational drug candidate IPI-504. U.S. Patent No. 7,282,493 includes composition of matter, pharmaceutical composition, method of treatment, and synthetic method claims directed to IPI-504 and other hydroquinone-containing ansamycin analogues. IPI-504, the companies' lead Hsp90 inhibitor, is currently being evaluated in two separate multi-center clinical trials in patients with gastrointestinal stromal tumors (GIST) and other soft tissue sarcomas, and in patients with non-small cell lung cancer. The patent is owned by Infinity and is co-exclusively licensed to MedImmune pursuant to the terms of the parties' collaboration agreement.